

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/058251 A2

(51) International Patent Classification⁷: **G01N 33/80**

(74) Agent: **NASH, David Allan**; Haseltine Lake, Imperial House, 15-19 Kingsway, London WC2B 6UD (GB).

(21) International Application Number: **PCT/GB03/00097**

(22) International Filing Date: 14 January 2003 (14.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: **0200721.9**
14 January 2002 (14.01.2002) **GB**

(71) Applicant (for all designated States except US): **UNIVERSITY OF THE WEST OF ENGLAND, BRISTOL** [GB/GB]; Frenchay Campus, Coldharbour Lane, Bristol, BS16 1QY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PURCELL, Wendy** [GB/GB]; Faculty of Applied Sciences, University of the West of England, Bristol, Coldharbour Lane, Bristol BS16 1QY (GB). **XU, Jinsheng** [CH/GB]; Faculty of Applied Sciences, University of the West of England, Bristol, Coldharbour Lane, Bristol BS16 1QY (GB).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **TOXICITY TEST**

A



B



C



(57) Abstract: An *in vitro* toxicity assay comprising: a) exposing a spheroid sample to a selected concentration of a compound to be assayed; b) incubating the spheroid sample for a suitable period of time; and c) observing if spheroid cell spreading inhibition takes place.

BEST AVAILABLE COPY

WO 03/058251 A2

-1-

TOXICITY TEST

The present invention relates to an *in vitro* toxicity assay using spheroids.

5 Spheroids have significant potential to be used as *in vitro* models to test the toxicity of compounds at various concentrations. The use of spheroids in an *in vitro* model as a repeatable and reliable indicator of toxicity is a desirable alternative to using live animals.

10 The inventors have developed a cell spreading inhibition test based on the observed spheroid cell growth, or "spreading" of cells in spheroids when the spheroids are grown on a suitable surface and at static state i.e. without shaking. As shown in Figure 1, the
15 cells grow out from the surface of the spheroid. It was found that when spheroids are exposed to a toxicant at a certain concentration, cell spreading is inhibited. This inhibition of cell spreading provides an indicator of toxicity.

20 According to a first aspect of the invention, there is provided an *in vitro* toxicity assay comprising:

- a) exposing a spheroid sample to a selected concentration of a compound to be assayed;
- 25 b) incubating the spheroid sample for a suitable period of time; and
- c) observing if spheroid cell spreading inhibition takes place.

30

35

-2-

At the selected concentration, if no cell spreading, or very limited spreading, of all the spheroids in the sample is observed relative to a control spheroid not exposed to the compound being assayed, this is
5 considered to be a spreading inhibition positive (+) result. However, if there is observable cell spreading from one or more of the spheroids in the sample, this is a cell spreading inhibition negative (-) result.

10 In the event that partial spreading is observed ie. there is some observable cell spreading in the sample, but not as extensive as in the control, then the assay should be repeated at a higher compound concentration to ensure that a conclusive result can be obtained, ie. a spreading inhibition positive (+) result.

15 When spheroid cell spreading inhibition occurs, this indicates that, at the selected concentration, the compound has a toxic effect on the cell type from which the spheroid sample is derived.

20 As used herein, the term "spheroid" means a three dimensional structure, typically substantially spherical in shape, which does not occur in nature and which consists of a re-aggregate of cells - typically containing 10^3 or more cells - of a tissue or of an organ or formed from cells lines either alone or in
25 combination.

The term "tissue" as used herein is taken to mean an organised selection of cells having a common function. The term "organ" is taken to mean an organised collection of "tissues" having a common function. The term "cell
30 line" is taken to mean a continuous cell culture derived from cells subject to transformation or otherwise having acquired to ability to divide continuously.

The "tissue" or "organ" need not be completely intact to be used in the present invention since parts of whole
35 tissues or organs (which may be obtained via biopsies) can be disrupted to individual cells/small groups of

cells before being re-aggregated to form spheroids used in the present invention.

Cells for use in producing spheroids for use in the present invention may be derived from any suitable
5 tissue source, including infected tissue. For spheroids comprising neuronal cells (e.g. brain spheroids), foetal tissue is preferred. For spheroids comprising other cells, tissue from both embryonic/foetal and non-foetal (e.g. adult sources) can generally be used. Liver
10 cells are particularly useful since they can be used to produce spheroids which retain some of the characteristics of the liver e.g. albumin secretion, urea secretion, glucose secretion and can therefore be used to model *in vitro* the metabolism of substances in
15 the liver and to explore general cytotoxic and specific hepatotoxic effects. This is useful, for example, in determining whether or not particular substances are likely to be toxic following metabolism by the liver and/or are directly toxic to the liver cells (i.e.
20 hepatotoxins) or interfere with generic cellular functionality.

Spheroids can, in principle, be produced from any desired tissue or organ from any animal by disrupting a sample of the tissue or organ, preferably to individual
25 cells or to small groups of cells. For example, mechanical disruption such as by gentle trituration through a Pasteur pipette can be employed for retinal and brain tissues. Alternatively, enzymatic digestion methods can be used, for example, for liver cell
30 dissociation.

Preferably, the spheroids of the present invention are derived from mammalian tissue or organs, such as from human, non-human primate, dog, rodent (including rat and Mouse) or porcine tissue or organs.
35 Alternatively, the spheroids of the present invention may be derived from fish tissue or organs.

Cells from cell lines may also be used. These may be initially cultured as a monolayer to generate more cells; trypsinization may be used for cell dissociation of a monolayer cell culture.

5 The spheroids used in the present invention may comprise two or more different cell types, whereby observation of cell spreading inhibition indicates that all the cell types making up the spheroid exhibit a toxic effect in response to the toxicant being tested.

10 Spheroids used in the present invention may be freshly prepared or may be obtained by thawing cryopreserved spheroids. Spheroids may be cryogenically prepared using methods such as that described in WO98/35021.

15 The *in vitro* assay of the present invention may be carried out using a series of different selected concentrations of the compound to be assayed, to provide an estimate of the threshold concentration at which the compound becomes toxic to the spheroid cell
20 type.

By carrying out the assay of the present invention using the same compound and different spheroid cell types, it may be possible to determine at what concentrations the compound is toxic to one cell type
25 and not to the other.

Brief Description of the Drawings

Figures 1A to 1C show spheroid cell spreading when spheroids are grown on a surface at static state;

Figures 2A to 2C show spheroid spreading in the
30 presence and absence of specific concentrations of galactosamine;

Figures 3A to 3C show spheroid spreading in the presence and absence of specific concentrations of propranolol;

35 Figures 4A and 4B show spheroid spreading in the presence of specific concentrations of diclofenac; and

Figures 5A and 5B show spheroid spreading the presence of specific concentrations of paracetamol.

In the following examples, fresh liver or HepG2 spheroids were used. Each test was repeated, to ensure that the same results were obtained and thereby ensure that the spheroid cell spreading inhibition test (SCSIT) is a reliable indicator of toxicity.

Preparation of liver spheroids

Liver spheroids were prepared from the liver of male Wistar rats by a two-step collagenase perfusion method described by Seglen P.O. ((1976). Preparation of isolated rat liver cells. Methods Cell. Biol. 13, 29-38) and modified by Lazar, A.; Peshwa, M.V., Wu, F.J., Chi, C.M., Cerra, F.B., and Hu, W.S. (1995). Extended liver-specific functions of porcine hepatocyte spheroids entrapped in collagen gel. In Vitro Cell Biol Anim. 31, 340-346). Viability of the isolated liver cells was determined by trypan blue dye exclusion i.e. an aliquot of isolated liver cells was mixed with an equal volume of trypan blue dye (1.0% w/v in isotonic saline) and incubated at room temperature for a minimum period of 5 minutes. Only isolated liver cell preparations with viability above 80% were used to prepare liver spheroids. The cell suspension was diluted with culture medium (hepatocyte medium supplemented with 5% FCS, 200 mM L-glutamine, 2 ng/ml insulin, 100 U/ml penicillin and 100 µg/ml streptomycin sulfate) to give a cell density of 5×10^5 cells/ml. The diluted cell suspension was dispersed into 6-well plates, 3 ml/well. The plates were incubated at 37°C, in a 5% CO₂ incubator on a gyrotatory shaker (New Brunswick) at an initial rotation speed of 85 rpm for the first 24 hr and 77 rpm thereafter. The plates were rotated at this speed for the duration of the study (up to 45 days, but typically 2-10 days). 1.5 ml of old medium was replaced with 2.0 ml fresh medium for each

-6-

well every other day. Media exchange was carried out over the duration of the study (up to 45 days, but typically 2-10 days).

Spheroids prepared using this protocol have a uniform size typically 170 μm , of which >80% are in the range of 160-180 μm .

Preparation of HepG2 spheroids

HepG2 cell line (Human Caucasian Hepatocyte Carinomal cells, from ECACC) was cultured as a monolayer in a 75 cm^2 flask at an initial density of 10^2 cells/ cm^2 in a culture medium containing MEM (Sigma) supplemented with 10% FBS, 200 nM L-Glutamine, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin (GibcoBril). HepG2 cells of confluent flasks were detached by trypsin and pooled together to be counted by trypan blue dye excretion. The cell suspension was diluted with culture medium (MEM supplemented with 5 % FBS, 200 nM L-glutamine, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin) to give 1×10^6 cell/ml cell suspension. The cell suspension was plated into 6-well plates, 3ml/well. The plate was placed on a gyrotatory shaker (New Brunswick) at 83 rpm in a 37°C CO₂ incubator for the first 24 h, and then the rotation speed reduced to 77 rpm. After 6 DIV culture, spheroids were ready for use.

EXAMPLE 1

3 to 5 freshly prepared spheroids were transferred into each well of a 24 well plate and exposed to galactosamine at various concentrations as detailed in Tables 1 and 2. Two wells were used for each concentration of galactosamine. The spheroids were incubated in Hepatocyte medium (Sigma) supplemented with 10-15% FCS, 200nM L-glutamine, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin sulfate, and placed in a 5%

CO₂ incubator at 37°C and the effects on spheroid cell spreading inhibition observed after 48 hours exposure of the cells to galactosamine:

5 Table 1 : SCSIT results using fresh liver spheroids

Batch	Control	4mM	10mM	16mM	20mM	40mM
A	-	-	-	-	+	+
B	-	-	-	-	+	+
C	-	-	-	-	+	+

Table 2 : SCSIT results using fresh HepG2 spheroids

Batch	Control	4mM	10mM	16mM	20mM	40mM
A	-	-	-	+	+	+
B	-	-	-	+	+	+
C	-	-	-	+	+	+

- 10 - indicates that no spheroid cell spreading inhibition was observed;
 + indicates that spheroid cell spreading was inhibited.

15 Figure 2A shows a control liver spheroid (with no exposure to galactosamine), 48 hours after cessation of rotation. No inhibition of spheroid cell spreading is observed. Figure 2B shows that 48 hours after exposure of a liver spheroid to galactosamine at a concentration of 16 mM, no spheroid cell spreading inhibition is
 20 observed. However, Figure 2C shows that 48 hours after exposure of a liver spheroid to galactosamine at a concentration of 40 mM, spheroid cell spreading was inhibited.

From Table 1, it can be seen that galactosamine inhibits liver spheroid cell spreading at concentrations of 20 mM and higher.

From Table 2, it can be seen that galactosamine
5 inhibits HepG2 spheroid cell spreading at concentrations of 16 mM and higher.

EXAMPLE 2

10 Freshly prepared spheroids were exposed to propranolol at various concentrations as detailed in Tables 3 and 4, and the effects on spheroid cell spreading inhibition observed:

Table 3 : SCSIT results using fresh liver spheroids

Batch	Control	62.5µM	125µM	250µM	500µM	1000µM
A	-	-	-	+	+	+
B	-	-	+	+	+	+
C	-	-	+	+	+	+

15 Table 4 : SCSIT results using fresh HepG2 spheroids

Batch	Control	62.5µM	125µM	250µM	500µM	1000µM
A	-	-	+	+	+	+
B	-	-	+	+	+	+
C	-	-	+	+	+	+

20 - indicates that no spheroid cell spreading inhibition was observed;
+ indicates that spheroid cell spreading was inhibited.

Figure 3A shows that 48 hours after exposure of a

liver spheroid to propranolol at a concentration of 125 μM , no spheroid cell spreading inhibition is observed.

However, Figure 3B shows that 48 hours after exposure of a liver spheroid to propranolol at a concentration of 250 μM , spheroid cell spreading was inhibited.

From Table 3, it can be seen that propranolol inhibits liver spheroid cell spreading at concentrations of 250 μM and higher.

From Table 4, it can be seen that propranolol inhibits HepG2 spheroid cell spreading at concentrations of 125 μM and higher.

EXAMPLE 3

Freshly prepared spheroids were exposed to diclofenac at various concentrations as detailed in Tables 3 and 4, and the effects on spheroid cell spreading inhibition observed:

Table 5: SCSIT results using fresh liver spheroids

Batch	Control	0.1 μM	1 μM	10 μM	100 μM	1000 μM
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

Table 6 : SCSIT results using fresh HepG2 spheroids

Batch	Control	0.1 μM	1 μM	10 μM	100 μM	1000 μM
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

-10-

- indicates that no spheroid cell spreading inhibition was observed;
 + indicates that spheroid cell spreading was inhibited.

5 Figure 4A shows that 48 hours after exposure of a liver spheroid to diclofenac at a concentration of 100 μM , no spheroid cell spreading inhibition is observed.
 However, Figure 4B shows that 48 hours after exposure of a liver spheroid to diclofenac at a concentration of
 10 1000 μM , spheroid cell spreading was inhibited.

From Tables 5 and 6, it can be seen that diclofenac inhibits both liver spheroid and HepG2 spheroid cell spreading at concentrations of 1000 μM and higher.

15 EXAMPLE 4

Freshly prepared spheroids were exposed to paracetamol at various concentrations as detailed in Tables 3 and 4, and the effects on spheroid cell
 20 spreading inhibition observed:

Table 7: SCSIT results using fresh liver spheroids

Batch	Control	5 μM	50 μM	500 μM	5mM	50mM
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

25 Table 8 : SCSIT results using fresh HepG2 spheroids

Batch	Control	5 μM	50 μM	500 μM	5mM	50mM
A	-	-	-	-	-	+
B	-	-	-	-	-	+

-11-

C	-	-	-	-	-	+
---	---	---	---	---	---	---

- indicates that no spheroid cell spreading inhibition was observed;

+ indicates that spheroid cell spreading was inhibited.

5

Figure 5A shows that 48 hours after exposure of a liver spheroid to paracetamol at a concentration of 5 mM, no spheroid cell spreading inhibition is observed.

10 However, Figure 5B shows that 48 hours after exposure of a liver spheroid to paracetamol at a concentration of 50 mM, spheroid cell spreading was inhibited.

15 From Tables 7 and 8, it can be seen that paracetamol inhibits both liver spheroid and HepG2 spheroid cell spreading at concentrations of 50 mM and higher.

SUMMARY

20 From the examples provided above, it is clear that when spheroids are exposed to a certain concentration of a toxicant, cell spreading is inhibited. This effect was observed with all four selected toxicants using both fresh liver and HepG2 spheroids. Therefore, spheroid cell spreading inhibition is a reliable, repeatable and stable indicator of toxicity.

25

30

CLAIMS

1. An *in vitro* toxicity assay comprising:
 - a) exposing a spheroid sample to a selected
5 concentration of a compound to be
assayed;
 - b) incubating the spheroid sample for a
suitable period of time; and
 - c) observing if spheroid cell spreading
10 inhibition takes place.
2. An *in vitro* toxicity assay according to claim 1,
wherein spheroid cell spreading inhibition indicates
that, at the selected concentration, the compound has a
15 toxic effect on the spheroid cell.
3. An *in vitro* toxicity assay according to claim 1 or
claim 2, wherein the spheroid cell is derived from
cells selected from the group consisting of neuronal
20 cells, liver cells and retinal cells.
4. An *in vitro* assay according to any preceding claim
wherein the spheroid sample is derived from a mammalian
cell.
25
5. An *in vitro* toxicity assay according to claim 4,
wherein the mammalian cell is a human, rodent, or
porcine cell.
- 30 6. An *in vitro* toxicity assay according to claim 4,
wherein the mammalian cell is a non-human primate or
dog cell.
7. An *in vitro* toxicity assay according to any one of
35 claims 1 to 3 wherein the spheroid sample is derived
from a fish cell.

8. An *in vitro* toxicity assay according to any preceding claim, wherein the spheroid cell is derived from a cultured cell line.

5

9. An *in vitro* toxicity assay according to any preceding claim, wherein the spheroid sample comprises more than one cell type.

FIG. 1A




FIG. 1 B




FIG. 1C




FIG. 2A




FIG. 2B





FIG. 2C



2/3

FIG. 3A




FIG. 3B





FIG. 4A



FIG. 4B



3/3

FIG. 5A





FIG. 5B



BEST AVAILABLE COPY